Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 6:51 PM
Ignite Modification Date:
2025-12-25 @ 4:24 PM
NCT ID:
NCT01097057
Group ID:
EG000
Title:
Treatment (Rituximab, Etoposide, Carboplatin, Ifosfamide)
Description:
Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
Carboplatin: Given IV
Etoposide: Given IV
Filgrastim: Given SC
Ifosfamide: Given IV
Leukapheresis: Given through catheter
Plerixafor: Given SC
Rituximab: Given IV
Deaths Number Affected:
5
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
20
Other Number Affected:
3
Other Number At Risk:
20
Study:
NCT01097057
Results Section:
NCT01097057
Adverse Events Module:
NCT01097057